Skip to main content
. Author manuscript; available in PMC: 2011 Apr 8.
Published in final edited form as: Cancer Res. 2008 Dec 1;68(23):9703–9711. doi: 10.1158/0008-5472.CAN-08-3084

Figure 6.

Figure 6

CD133+ prostate cancer cells express the AR. Dual-variable flow cytometry of CD133 (AC141) and AR in the LAPC-4, LNCaP, and CWR22Rv1 prostate cancer cell lines. Top, control staining in LAPC-4 using IgG antibodies (top left, CD133 versus IgG; top right, IgG versus AR). Similar controls were documented in the LNCaP and CWR22Rv1 cell lines. Bottom, dual labeling for CD133 and AR in LAPC-4, LNCaP, and CWR22Rv1 prostate cancer cells showing that CD133+ prostate cancer cells also express AR.